OSR Holdings discloses talks on SillaJen stake and Pexa-Vec licensing

OSR Holdings has disclosed ongoing negotiations regarding a stake in SillaJen and a licensing agreement for cancer treatment Pexa-Vec. The talks suggest potential deal activity in the biotech and pharmaceutical space. This development could have significant implications for the commercialization of Pexa-Vec as an oncology therapy.